Answers are grounded in this paper and cite their sources.
Dibenzosuberone (DBS) is a key intermediate for the synthesis of relevant active pharmaceutical ingredients (APIs) for the treatment of several diseases related to the central nervous system. Herein, the design and development of a milder and greener approach to improve the well‐established methodology for the synthesis of DBS limiting waste production via the use of immobilized catalysts are presented.
No takes yet. Share an insight, caveat, or question.
Nori et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: